Transdermal delivery of propranolol hydrochloride through chitosan nanoparticles dispersed in mucoadhesive gel by Al-Kassas, R et al.
 Al-Kassas, R, Wen, J, Cheng, AE-M, Kim, AM-J, Liu, SSM and Yu, J
 Transdermal delivery of propranolol hydrochloride through chitosan 
nanoparticles dispersed in mucoadhesive gel
http://researchonline.ljmu.ac.uk/id/eprint/12325/
Article
LJMU has developed LJMU Research Online for users to access the research output of the 
University more effectively. Copyright © and Moral Rights for the papers on this site are retained by 
the individual authors and/or other copyright owners. Users may download and/or print one copy of 
any article(s) in LJMU Research Online to facilitate their private study or for non-commercial research. 
You may not engage in further distribution of the material or use it for any profit-making activities or 
any commercial gain.
The version presented here may differ from the published version or from the version of the record. 
Please see the repository URL above for details on accessing the published version and note that 
access may require a subscription. 
For more information please contact researchonline@ljmu.ac.uk
http://researchonline.ljmu.ac.uk/
Citation (please note it is advisable to refer to the publisher’s version if you 
intend to cite from this work) 
Al-Kassas, R, Wen, J, Cheng, AE-M, Kim, AM-J, Liu, SSM and Yu, J (2016) 
Transdermal delivery of propranolol hydrochloride through chitosan 
nanoparticles dispersed in mucoadhesive gel. Carbohydrate Polymers, 153. 
pp. 176-186. ISSN 0144-8617 
LJMU Research Online
1 
 
Transdermal delivery of propranolol hydrochloride through chitosan 1 
nanoparticles dispersed in mucoadhesive gel 2 
 3 
*Raida Al-Kassas, Jingyuan Wen, Angel En-Miao Cheng, Amy Moon-Jung Kim, 4 
Stephanie Sze Mei Liu, Joohee Yu 5 
 6 
School of Pharmacy, Faculty of Medical and Health Sciences, University of Auckland, 7 
Auckland, New Zealand. 8 
 9 
 10 
 11 
Corresponding Author: 12 
*Dr Raida Al-Kassas 13 
School of Pharmacy 14 
Faculty of Medical and Health Sciences 15 
The University of Auckland 16 
Private Bag 92019 17 
Auckland  18 
New Zealand 19 
Email: r.al-kassas@auckland.ac.nz 20 
 21 
 22 
 23 
 24 
 25 
 26 
 27 
 28 
 29 
 30 
 31 
 32 
 33 
2 
 
Abstract 34 
This study aimed at improving the systemic bioavailability of propranolol-HCl by the design 35 
of transdermal drug delivery system based on chitosan nanoparticles dispersed into gels. 36 
Chitosan nanoparticles were prepared by ionic gelation technique using tripolyphosphate 37 
(TPP) as a cross-linking agent. Characterization of the nanoparticles was focused on particle 38 
size, zeta potential, surface texture and morphology, and drug encapsulation efficiency. The 39 
prepared freeze dried chitosan nanoparticles were dispersed into gels made of poloxamer and 40 
carbopol and the rheological behaviour and the adhesiveness of the gels were investigated. 41 
The results showed that smallest propranolol loaded chitosan nanoparticles were achieved 42 
with 0.2% chitosan and 0.05% TPP. Nanoparticles were stable in suspension with a zeta 43 
potential (ZP) above ± 30 mV to prevent aggregation of the colloid. Zeta potential was found 44 
to increase with increasing chitosan concentration due to its cationic nature. At least 70% of 45 
entrapment efficiency and drug loading were achieved for all prepared nanoparticles. When 46 
chitosan nanoparticles dispersed into gel consisting of poloxamer and carbopol, the resultant 47 
formulation exhibited thixotropic behaviour with a prolonged drug release properties as 48 
shown by the permeation studies through pig ear skin. Our study demonstrated that the 49 
designed nanoparticles-gel transdermal delivery system has a potential to improve the 50 
systemic bioavailability and the therapeutic efficacy of propranolol-HCl. 51 
 52 
Keywords: Propranolol-HCl; Chitosan nanoparticles; gels; transdermal drug delivery. 53 
 54 
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1. Introduction 67 
The transdermal route has been a topic of interest for many years and is generally regarded as 68 
a “patient friendly” option due to the avoidance of gastrointestinal side effects which usually 69 
entail many oral preparations. Not only it avoids first pass metabolism and varying acidic 70 
conditions of the gastrointestinal tract, it can also be used to maintain a constant, prolonged 71 
and therapeutically effective drug concentration in the body. Transdermal drug delivery also 72 
avoids fluctuations in plasma drug concentration, which helps minimising adverse effects and 73 
therapeutic failure (Tanner and Marks, 2008). The main challenge in transdermal drug 74 
delivery however, is to overcome the inherent barrier of the skin. It has been reported that  75 
the rate limiting step in transdermal delivery is the ~ 30 µm thick stratum corneum which acts 76 
as the primary barrier for the diffusion and drug penetration ( Cevc and Vierl, 2009). Various 77 
strategies have been followed to improve delivery of drugs through skin among these is the 78 
use of nanoparticulate carriers based on polymers (Prow et al., 2011).  79 
 80 
Chitosan is a cationic polysaccharide made of 2-acetamido-2-deoxy-d-glucose (N-acetyl 81 
glucosamine, GlcNAc), and 2-amino-2-deoxy-d-glucose (glucosamine, GlcNH2) with β-d-(1 82 
→ 4) glycoside linkages as shown in Figure 1.a. Types of chitosan are differentiated by the 83 
degree of N-acetylation (DA). Chitosan contains free amino groups which render it insoluble 84 
in water. However, the amino groups undergo protonation in acid and therefore it becomes 85 
soluble in aqueous solution. It has very low toxicity and breaks down slowly to harmless 86 
products (amino sugars) which are absorbed by the body (Arai et al., 1968). Chitosan is also 87 
recognized as a permeation enhancer due to its mucoadhesive properties. It binds to the 88 
epithelial cell membrane and the positive charges result in F-actin depolymerisation and 89 
disbandment of the tight junction protein ZO-1, leading to opening the tight junctions.  With 90 
all these attributes, chitosan is a desirable polymer and therefore has been widely used in 91 
preparation of micro- and nanoparticles (Agnihotri et al., 2004). 92 
 93 
Nanoparticles are characterised by a mean particle diameter of ≤ 1 µm (Gan et al., 2005). 94 
These colloidal polymeric drug carriers are used to protect drugs from premature degradation 95 
and prevent interaction with the biological environment. Furthermore, they enhance 96 
bioavailability, absorption and penetration into the specific target tissues ( Budhian et al., 97 
2007). Since drug uptake at the cellular level is size-dependent, smaller particles are taken up 98 
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to a higher extent ( Ubrich et al., 2004). It has been reported that a particle size of less than 99 
500 nm is crucial for transdermal delivery (Kholi and Alpar, 2004).  100 
For topical application, nanoparticulate systems are needed to be dispersed into suitable 101 
semisolid vehicle such as hydrogels to maintain adherence on the skin. However, when 102 
dispersed, the characteristics of the dispersed systems as well as the vehicle may be affected. 103 
 104 
 105 
 106 
Figure 1.a. Structure of chitosan 107 
 108 
Propranolol (PLN) (Figure 1.b), a non-selective β-blocking agent is commonly used for 109 
cardiovascular conditions such as hypertension, angina pectoris and cardiac arrhythmia. 110 
Propranolol has only an approximate half-life of 4 hours which requires frequent dosing to 111 
maintain a therapeutic effect. Although PNL is rapidly absorbed from the gastrointestinal 112 
tract, high oral doses are necessary due to an oral bioavailability of less than 23%, extensive 113 
first-pass metabolism and susceptibility to enzymatic degradation. It is currently available as 114 
an oral preparation and an intravenous formulation which is usually exclusive for hospital 115 
use.  116 
 117 
     118 
Figure 1.b: Structure of PNL and PNL-HCl 119 
 120 
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The aim of this study was to develop a transdermal delivery system for propranolol based on 121 
chitosan nanoparticles dispersed into gels in attempt to improve the systemic bioavailability of 122 
the drug. The properties of the nanoparticles as well the gels before and after dispersion of 123 
nanoparticles into gels were evaluated. 124 
 125 
2. MATERIALS AND METHODS 126 
2.1 Materials 127 
Propranolol-HCl, medium molecular weight chitosan and pentasodium tripolyphosphate (TPP) 128 
were purchased from Sigma-Aldrich Chemical Co. Ltd (New Zealand). Carbopol 940 129 
(carbopol) was purchased from Lubrizol Advance Materials, Inc (USA) and Poloxamer 407 130 
was purchased from BASF (Germany). 131 
 132 
2.2 Formulation and characterisation of nanoparticles 133 
2.2.1 Preparation of nanoparticles 134 
Nanoparticles were prepared by the ionic gelation method (Gan et al., 2005) at room 135 
temperature with combinations of chitosan (0.1%, 0.2%, 0.3%) and TPP (0.02%, 0.05%, 136 
0.08%) in triplicates. Chitosan was dissolved in acetic acid solution adjusted to pH 4.5 and 137 
TPP was dissolved in Milli-Q water. TPP solution was added dropwise to an equal volume of 138 
chitosan solution under magnetic stirring at 650 rpm over 60 minutes. The formed 139 
nanoparticles were immediately analyzed for particle size and zeta potential in order to obtain 140 
appropriate polymer concentrations for further investigation of propranolol-loaded chitosan 141 
nanoparticles. 142 
Propranolol-loaded chitosan nanoparticles were prepared by the same method mentioned 143 
above, but that the appropriate amount of PNL was dissolved in chitosan solution before the 144 
dropwise addition of TPP solution. To study the effect of propranolol concentration on the 145 
physicochemical properties of nanoparticles, chitosan 0.3% was used in the ratio of 146 
propranolol to chitosan at 1:1, 2:1 and 3:1. Whereas to study the effect of chitosan 147 
concentration, 20 mg of propranolol was used in the ratio of propranolol to chitosan at 1:0.5, 148 
1:1, and 1:1.5. 149 
2.2.2 Particle size and zeta potential measurements: 150 
Particle size, zeta potential and polydispersity index (PDI) of nanoparticle formulations were 151 
measured using a Zetasizer Nano Series Nano-NS (Malvern Instruments, UK). Each sample 152 
was measured in triplicate and the average results were calculated.  153 
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Total drug added 
2.2.3 Determination of entrapment efficiency:  154 
The entrapment efficiency of propranolol was calculated by measuring the amount of free 155 
drug left in supernatant after centrifugation. Briefly nanoparticle suspensions were 156 
centrifuged (Eppendorf MiniSpin Plus Microcentrifuge) at 13,000 rpm for 30 min. The 157 
supernatants were diluted and amount of recovered propranolol was determined 158 
spectrophotometric ally at 280 nm. The entrapment efficiency was calculated using the 159 
following equation:  160 
 161 
% EE = (Total drug added – free drug)   x 100 162 
 163 
2.2.4 Morphology of propranolol loaded chitosan nanoparticles: 164 
The morphology of freshly prepared and freeze dried propranolol-loaded chitosan 165 
nanoparticles were examined using scanning electron microscopy. Samples were coated in a 166 
polaron Sc7640 sputter coater and analyzed by a Phillips x L30SFG with SiLi (Lithium 167 
drifted) super ultra Thin Window EDS detector.   168 
2.3 Formulation and characterisation of gels 169 
2.3.1 Formulation of gels 170 
Poloxamer gels (15% w/v) were prepared using the cold technique. Poloxamer was slowly 171 
added to certain volume of cold Milli-Q water (5-10 ºC) with constant stirring for 60 min at 172 
650 rpm. Additional amount of Cold Milli-Q water was added to the solution at 30 min to 173 
make up to the volume. Poloxamer solutions were kept in the refrigerator (4-5 ºC) overnight 174 
then kept at room temperature for a further 24 hrs ( Singh et al., 2009). 175 
Carbopol 940 (1% and 2% w/v) gels were prepared by dispersing appropriate amount of 176 
carbopol into certain volume of Milli-Q water at room temperature with constant stirring for 177 
60 min at 650 rpm (9). Milli-Q water was added to the solution at 30 min to make up the 178 
volume to the total amount. Carbopol gels were kept at room temperature for 24 h. 179 
15% poloxamer / 1% carbopol combination gels were prepared with similar methods as 180 
above. Poloxamer was dissolved in cold Milli-Q water and carbopol was separately dissolved 181 
at room temperature in Milli-Q water of the same volume. Both were stirred at 650 rpm for 182 
60 min. At 30 min, the two were mixed and Milli-Q water was added to the mixture with 183 
stirring to make up the volumes to the total amount. These gels were kept at room 184 
temperature for 24 h. 185 
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Each of the above gels containing 0.6% (w/v) propranolol-HCl was prepared separately. 186 
Similar steps as above were followed except propranolol-HCl was dissolved in a small 187 
volume of Milli-Q water before the final gels were made up to the volume. pH of all of the 188 
gels were adjusted to 5.5. 189 
2.4 Formulation of nanoparticles/gels transdermal delivery systems: 190 
The nanoparticulate system and gel were selected after studying different parameters 191 
affecting the formulations. The selected freeze dried nanoparticulate system was incorporated 192 
into the gel, and the characteristics of resultant transdermal delivery systems was evaluated 193 
and compared with gels containing drug.  194 
2.4.1  Rheological measurements: 195 
The rheological behaviours of the gel and transdermal delivery system formulations 196 
consisting of nanoparticles dispersed into gel were measured at 25 ºC and 33 ºC (Digital 197 
Viscometer Brookfield DV-III). Measurement at 33 ºC was required to represent the skin 198 
temperature. Spindle sizes (CP40 and CP52) were used depending on the thickness of the gel 199 
and shear rate adjustments for a torque between 5-100%. 200 
2.4.2 Texture analysis 201 
Adhesive capacity of gels and transdermal delivery systems were measured using (Stable 202 
Micro System Texture Analyser TA. XT. Plus). The adhesive test settings were as follows; 203 
test speed=0.5 mm/sec, force applied=100 g, contact time=5 seconds, trigger force=5 g. 204 
Maximum force (N) was recorded from the texture analysis graph. 205 
2.4.3 Preparation of pig ear skin: 206 
Fresh male pig ears were obtained from the abattoir (Auckland Meat Processors, Auckland, 207 
New Zealand). Ears were washed with water and dried. The subcutaneous tissue of the skin 208 
was carefully removed using a scalpel to retain the stratum corneum of the skin. The skin 209 
specimen was cut into appropriate sizes and washed with normal saline. 210 
2.4.4  In vitro and ex vivo drug permeation studies 211 
In vitro and ex vivo drug permeation studies were conducted with Franz diffusion cells (FDC- 212 
6 Logan Instruments Corp). Cellulose membrane or freshly excised pig ear skin were 213 
mounted between the donor and receptor cell (stratum corneum side facing the donor). For 214 
the ex vivo permeation study, pig stratum corneum was equilibrated in Franz cells overnight 215 
for hydration (El Maghraby, 2009). The receptor compartment was filled with pH 6.8 PBS 216 
and its temperature was maintained at 37  1 °C by circulating water bath in order to ensure 217 
that the surface membrane temperature was 32  1 °C (Wissing and Müller, 2002). The 218 
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donor compartment contained the following samples; propranolol loaded chitosan 219 
nanoparticle suspension, gels and nanoparticles in gels. 0.5 mL samples were withdrawn at 220 
different time intervals and replaced with an equal quantity of PBS into the receptor 221 
compartment (Parsaee et al., 2002). All samples were analysed for propranolol content by 222 
spectrophotometer at 280 nm (UV/Visible Spectrophotometer Libra S32PC).  223 
SEM imaging was taken for pig stratum corneum used in ex vivo release study and was 224 
compared with untreated pig stratum corneum (Herkenne et al., 2006). 225 
 226 
3. Results and discussion: 227 
3.1 Formation and physicochemical properties of chitosan nanoparticles: 228 
Particle size is one of the most important factors in the development of nanoparticles, 229 
especially for transdermal delivery as there are evidences of skin penetration of very small 230 
nanoparticles into viable tissues (Ryman-Rasmussen et al., 2006; Zhang et al., 2008).  231 
Table 1 shows the effect of polymer and TPP concentration on nanoparticle parameters 232 
prepared without drug. The smallest drug free nanoparticles were achieved with 0.2% 233 
chitosan and 0.05% TPP as they were in the size range of 160-210 nm. This was found to be 234 
the optimum polymer to TPP ratio for favourable electrostatic interactions to yield small 235 
nanoparticles. 236 
The polydispersity index (PDI) which describes the size distribution was also the least for the 237 
combination of 0.2% chitosan and 0.05% TPP. Nanoparticles formulated with 0.1% chitosan 238 
were significantly larger than those obtained using 0.2% and 0.3% of chitosan with minimal 239 
variation between the latter two. de Moura et al. (2009) reported an opposite trend where an 240 
increase in particle size was observed with increasing chitosan concentration. They explained 241 
the reason for their findings as the solubility of chitosan becomes less at increasing 242 
concentrations leaving free particles to aggregate. However the trend observed in this study 243 
can be a consequence of the CS/TPP ratio as the ratio is another significant factor that can 244 
impact the particle size (Ricci et al., 2005). Table 1 shows that 0.02% and 0.08% 245 
concentrations of TPP generally produced larger nanoparticles than 0.05% TPP. Wide PDI 246 
was achieved with 0.1% and 0.3% chitosan whereas 0.2% chitosan showed a narrow PDI 247 
indicating that nanoparticles with this polymer concentration possessed more uniform 248 
nanoparticle size. 249 
All nanoparticle formulations reported in the table are suitable for transdermal delivery as 250 
they are less than 500 nm in size. Zeta potential reflects the density of the surface charge and 251 
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is influenced by the composition of the particles and the medium in which they are dispersed 252 
(Mohanraj and Chen, 2007). In aqueous solution, chitosan changes its conformation and 253 
becomes more flexible even with the presence of TPP, and the overall surface charge 254 
becomes positive. Nanoparticles with zeta potential above ± 30mV are stable in suspension 255 
due to the repulsion of surface charge preventing aggregation of nanoparticles ( Mohanraj and 256 
Chen, 2007). Table 1 shows the zeta potential increased with ascending chitosan 257 
concentration due to its cationic nature. However the zeta potential of nanoparticles prepared 258 
with 0.08% TPP was less compared to those prepared with other concentrations which may 259 
be due to polyanionic nature of TPP.  260 
 261 
The concentrations of propranolol-HCl have been varied in our research in order to study its 262 
effect on the properties of the nanoparticles (Table 2). Nanoparticles containing 0.2% 263 
chitosan and 0.05% TPP were used for this study. Generally, there was an increase in size 264 
and  zeta potential of the nanoparticles with the addition of propranolol-HCl.  However, 265 
smaller nanoparticles were achieved with 1:2 chitosan to propranolol-HCl ratio at 266.47 nm. 266 
The table shows that the zeta potential decreases as the concentration of propranolol increases 267 
in the formulation which was possibly because of interactions between the positively charged 268 
chitosan and negatively charged propranolol-HCl.  269 
Table 3 illustrates the effect of increasing chitosan content in propranolol loaded chitosan 270 
nanoparticles. Nanoparticles consisting of 0.2% chitosan and 0.05% TPP were used for this 271 
experiment. The table shows that 1:1 chitosan to propranolol-HCl ratio produced particles 272 
with average size of 166.53 nm which is comparable to the size of drug free nanoparticles 273 
prepared at the same chitosan and TPP content. This may be due to the favourable ratio of 274 
cationic and anionic charges between the polymers, TPP and propranolol-HCl. The zeta 275 
potential of this formulation was found to be > ±30 mV indicating good physical stability of 276 
nanoparticles. PDI has increased with drug incorporation. This may be again due to the 277 
aggregation of nanoparticles as explained above. When propranolol-HCl was increased (table 278 
2), an increase in entrapment efficiency and drug loading was observed due to the increased 279 
drug available for incorporation into the nanoparticles. However at constant propranolol-HCl 280 
concentration (table 3) a decrease in entrapment efficiency and drug loading occurred with 281 
increasing chitosan concentrations possibly due to the increase of electrostatic repulsion 282 
between chitosan polymers. The high drug loading ability and small nanoparticles 283 
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demonstrated to provide a positive prospect for the further development of the nanoparticles 284 
for transdermal delivery. 285 
The SEM micrographs of PNL-HCl loaded nanoparticles (Figure 2) have shown that most of 286 
nanoparticles were less than 300nm. However, there was some aggregation of nanoparticles 287 
which could be due to unpurified chitosan. After freeze-drying of PNL-HCl-loaded 288 
nanoparticles, the fluffy and feathery appearance of nanoparticles was observed (Figure 3). 289 
This structure shows hygroscopic properties thus it is readily dispersible in aqueous phase. 290 
 291 
From this part of the study it can be concluded that, 0.2% chitosan and 0.05% TPP were 292 
selected as the nanoparticulate system for the final formulation and to be incorporated into 293 
the selected gel as this combination provides the smallest size and suitable zeta potential with 294 
high entrapment efficiency and PNL-HCl loading into nanoparticles. 295 
3.2 Rheological behaviour of the formulated gels 296 
Nanoparticles suspension has low viscosity and therefore the particles will not remain on the 297 
skin surface for drug absorption and penetration to take place. To overcome this problem, the 298 
selected propranolol nanoparticles formulation was incorporated into gels made of mixture of  299 
poloxamer and carbopol as these are the most widely used polymers in gel formulation.  300 
In this study, we have investigated the rheological properties of gels prepared from either 301 
poloxamer or carpobol with and without presence of the drug. We also investigated the 302 
changes that happen to the rheological properties of these gels when they were combined 303 
together before and after incorporation of the nanoparticles.  304 
The rheological characterization was conducted at room temperature 25°C and skin 305 
temperature 33°C. In order to maintain the consistency of pH and optimum gel viscosity, few 306 
drops of 1M NaOH were added for pH adjustment to 5.5, this method is suitable for both 307 
poloxamer and carbopol gels as mentioned by Lu et al. (1998). Figure 4 shows shear stress 308 
versus shear rate of carbopol gels. The shear stress increased by increasing the shear rate. 309 
Figure 5 shows a decrease in gel viscosity by increasing the shear rate indicating shear 310 
thinning (pseudo-plastic) behavior of the gel.  Poly (acrylic acid) carbopol is a pH sensitive 311 
polymer. It changes to stiff gel in aqueous solution when the pH is raised. In our study, 312 
addition of NaOH to adjust the pH may have increased carpobol ionization in the aqueous 313 
solution and resulted in electrostatic repulsion between the adjacent carboxyl groups and an 314 
expansion of the polymer network. From figure 4 it can be seen that 2% carbopol gel 315 
possessed higher shear stress than 1% carbopol gel for the same shear rate exerted. This could 316 
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be due to the increased amount of polymer available leading to increased electrostatic 317 
repulsion, polymer swelling and consequently increased elastic solid behavior. No marked 318 
difference in the shear stress was observed when the temperature was increased from 25 to 319 
33°C. This indicates that pH and polymer concentration are the major factors contributing to 320 
gelling properties of carbopol. 321 
The flow curves of poloxamer formulations (Figure 6) at the experimental conditions 322 
investigated exhibited a Newtonian flow as demonstrated by a linear increase in shear stress 323 
with increasing shear rate. Poloxamers are in situ gelling polymers as they perform sol to gel 324 
transition by enhancement of the elasticity network when the temperature increases (Santos et 325 
al., 2015). It has been reported that when the concentration and temperature of the polymer 326 
are above a critical value, poloxamer molecules in aqueous solution will self assemble to 327 
form spherical micelles with a dehydrated PPO core surrounded by hydrated swollen PEO 328 
chain (Dholakia et al., 2012). Therefore gelation in this case, is the result of micelles 329 
entanglement and packing. Thus the results presented in Figure 6 suggest that the poloxamer 330 
solutions didn’t undergo phase transition to turn into gels and remained as free flowing 331 
liquids. This could be due to that the experiments were conducted at conditions below the 332 
gelation temperature of poloxamer which is 36°C therefore the molecular structure of the 333 
polymer solution didn’t change. The flow curves presented in figure 7 confirm these findings 334 
and reveal that the viscosity remained constant by increasing the shear rate.  335 
When carpobol and poloxamer gel were mixed the rheological properties of the resultant 336 
system have changed significantly. The rheograms presented in Figure (8) show thixotropic 337 
behaviour of gels consisting of combination of carbopol and poloxamer and containing either 338 
propranolol-HCl or propranolol loaded nanoparticles as the downward curve was displaced 339 
with regards to upward curve. Thixotropy can be defined as isothermal and a slow recovery 340 
upon  standing of a material of a consistency lost through shearing. These systems are 341 
characterized by a decrease in viscosity when they are subjected to shear stress due to the 342 
time dependant reformation of the secondary structure. Figure 8 also shows that hysteresis 343 
loop formed by the up and down curves of the rheogram is bigger for combination gel 344 
containing propranolol nanoparticles than that for gel containing drug alone indicating greater 345 
magnitude of structural breakdown and thixotropy of this formulation. This is a desirable 346 
property for a topical formulation as the greater the thixotropy, the lower is the settling and 347 
sedimentation rate of the nanoparticles in the system. The viscograms presented in Figure 9 348 
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show that all combination gels possessed non-Newtonian, pseudoplastic (shear thinning) 349 
behaviour.  350 
 The complex rheological properties of systems consisting of nanoparticles dispersed in gels 351 
was also reported by others (Chawla and Saraf, 2012).  352 
3.3 Adhesive capacity of the gels 353 
Transdermal delivery system should possess desirable adhesiveness as weak adhesion may 354 
results in incomplete absorption of drug through skin. In this study, the adhesiveness of the 355 
designed transdermal delivery systems was investigated and the results are presented in 356 
Figure 10. The adhesive capacity is dependent on the type and concentration of bioadhesive 357 
polymer used in the formulation. In formulation based on Carpobol, the adhesiveness of the 358 
gel increased as the concentration of the polymer increased. This may be attributed to the 359 
increased number of the hydrophilic carboxyl functional groups available for binding, but 360 
may also be a function of increased tack of the gel. Choi et al. (1998) have reported an 361 
increase in the adhesive forces of gels by increasing carbopol concentration. From the figure, 362 
it can be seen that poloxamer solution possessed significantly lower adhesiveness than 363 
Carbopol gel. However, combining carbopol to poloxamer has increased the adhesive 364 
properties of both polymers. These results are in agreement with Qi et al., 2007 who 365 
demonstrated an increase in mucoadhesive force of ophthalmic gels when Carbopol was 366 
incorporated into poloxamer solution. The possible explanation for these finding is the 367 
combined effects of hydrophilic oxide groups of poloxamer and the carboxyl group of 368 
carbopol which has improved the binding capacity of the formulation to the underlying 369 
surface through electrostatic and hydrophobic interaction.  370 
With the addition of propranolol-HCl, the adhesive force of carbopol gels decreased. The 371 
effect on poloxamer gels was more substantial with an approximate 75- 80% drop in the 372 
adhesive force. Propranolol-HCl causes a decrease in adhesive due to its positive charge 373 
which can interact with the negatively charged of carbopol to form a complex.  This 374 
decreases the negative charge repulsions between carbopol polymers which uncoil and 375 
expand, leading to reduction in polymer swelling and gel formation. On the other hand, the 376 
hydroxyl group of propranolol molecules can form hydrogen bond with the PEO block of 377 
poloxamer molecules (Kim et al., 2002) which may have been responsible for the adhesive 378 
force becoming reduced. Interestingly, the contrary was observed for poloxamer and carbopol 379 
combination gels. An increase in adhesive force was observed for the combination gels from 380 
1.35 to 1.76 N after incorporation of propranolol-HCl. The observed increase can be 381 
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explained by the steric stabilisation properties of poloxamer which prevents the interaction 382 
between propranolol-HCl and carbopol so that the cross-linking, viscoelastic properties of 383 
carbopol can be potentiated. 384 
The formulation of poloxamer 15% and carbopol 1% containing nanoparticles loaded with 385 
propranolol-HCl had an adhesive force of 0.60 N.  The chitosan component of the 386 
nanoparticles carries a positive charge which can also interact with carbopol. It is observed to 387 
cause a significant difference in the adhesion of gels compared with the addition of 388 
propranolol-HCl due to the increased positive charge preventing the electrostatic repulsions 389 
between carbopol. 390 
3.4 In vitro drug release study 391 
The effect of the type of transdermal formulation on the release of propranolol through 392 
cellophane membrane was investigated and the results are illustrated in Figure 11. The 393 
release profiles followed predictable trends in relation to each other. For propranolol 394 
containing buffer solution, the release of propranolol was very rapid and approximately 65% 395 
of drug was released in 24 h. However, when propranolol-HCl was dispersed in combination 396 
gel system, the release rate has reduced significantly. It was thought that this effect was the 397 
result of combining the swollen carbopol with poloxamer solution which has increased the 398 
density of the chain structure of the gel and reduced the diffusion of propranolol through the 399 
formulation. Figure 11 shows chitosan nanoparticles yielded lowest cumulative mass of drug 400 
released. Only 7% and 11 % of propranolol was released in 24 hours from the nanoparticle 401 
suspension and nanoparticle/gel. This can be explained by the sustained release properties of 402 
cross-linked chitosan and hydrophobic interactions with propranolol-HCl has led to a delayed 403 
and an incomplete release of drug from the nanoparticles ( Ubrich et al., 2004). It was noticed 404 
that the burst effect from these systems was negligible and release profiles were almost 405 
linear. Generally, the release of propranolol from each formulation remained steady after 10 h 406 
except for propranolol in gel which was shown to increase until at least 24 h. 407 
3.5 Ex vivo drug release study 408 
Permeation studies were conducted in an attempt to assess the effect of the nanoparticles-Gel 409 
transdermal system on the skin uptake and permeation properties of propranolol. The studies 410 
were performed across pig ear skin since it can be considered as a reasonable model for 411 
human barrier (Testa et al., 2001). The % cumulative mass of propranolol permeated across 412 
the skin of different transdermal formulations over 24 hrs is shown in Figure 12. An initial 413 
burst of drug permeation was noticed from the formulations in the first 5hrs, after which the 414 
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drug continued to permeate slowly and steady. The permeation profiles have exhibited zero 415 
order kinetics with r2 values of 0.9911, 0.9973 and 0.9622 for gel, nanoparticles suspension 416 
and nanoparticles in gel respectively. Of all formulations investigated, gel showed the highest 417 
permeation rate. This can be explained by the high drug release properties of the gel system 418 
which resulted in an increase in drug concentration in the donor compartment and an increase 419 
of the concentration gradient towards the skin. Figure 12 shows that the permeation rate of 420 
propranolol from nanoparticles in gel was the lowest. It has been reported that both high and 421 
low permeation rates are of interest in skin application. Enhanced permeation rate can 422 
improve drug permeability through skin whereas; sustained release can provide the skin with 423 
drug over long period of time. It was noticed that The Papp values (Table 4) have confirmed 424 
the permeation profiles results and they have followed this order which is gel > nanoparticle 425 
suspension> nanoparticles in gel. The same trend was also observed from release studies. The 426 
fact that trend of Papp values is the same as the release rate from formulations suggests that 427 
the mechanism of propranolol permeation through the skin is formulation controlled rather 428 
than skin controlled. In an attempt to support this finding, the skin uptake effect was followed 429 
using scanning electron microscopy. The SEM micrographs of untreated and treated pig 430 
stratum conium with nanoparticles in gel formulation are shown in Figure 13 (a&b). Figure 431 
(a) indicates that there are unblocked and clear pores before treatment. However, after 432 
treatment the micrograph reveals no clear pore since the nanoparticles have penetrated 433 
through the stratum cornium and blocked all the pores. One of the interesting properties of 434 
chitosan is that it can widen the tight junctions between the mucoepithelial cells reversibly by 435 
interaction of the protonated CS with anionic components of glycoprotein on the surface of 436 
the epithelial cells and with fixed negative charges in the interior of the tight junction, which 437 
lead to absorption enhancement of the drug (Yeh et al., 2011). Therefore, presence of 438 
nanoparticles in gel have increased their contact time with the skin and the properties of 439 
chitosan might have affected the stratum cornuim nature and widened the tight junctions and 440 
pores in the skin and allowed the particles to be up taken. Although the Ex vivo studies 441 
showed slow permeation rate from nanoparticles in gel over 24 hours, however the results of 442 
the SEM suggest that nanoparticles uptaken will create a reservoir of drug within the skin 443 
where it provide the system over long period of time with small doses of propranolol to 444 
control the systemic blood pressure. From these results it can be concluded that the type of 445 
formulation and its unique properties have affected and both the permeation rate of drug and 446 
its concentration within the skin. 447 
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4. Conclusion 448 
The present work showed that transdermal delivery system for propranolol based on chitosan 449 
nanoparticles dispersed into gel was successfully prepared and characterized. The novel gel 450 
formulation exhibited thixotropic behaviour with a prolonged drug release properties as shown 451 
by the permeation studies through pig ear skin. Furthermore, the SEM images showed that 452 
the chitosan nanoparticles were uptaken by the skin which may create a drug reservoir to 453 
provide the system with propranolol over long period of time to control the blood pressure. 454 
Thus, the nanoparticles gel could be a promising transdermal delivery system for propranolol 455 
however, in vivo studies are necessary to confirm this conclusion. 456 
 457 
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Table 1: 592 
Effect of chitosan and TPP concentrations on the physical properties of the nanoparticles 593 
 594 
 
Particle size (nm) ± 
SD 
Average PdI 
± SD 
Average ZP 
(mV) ± SD % Chitosan % TPP 
     0.1 
 
  
 
0.02 462.59 ± 212.26 0.49 ± 0.27 15.97 ± 4.67 
0.05 311.72 ± 111.70 0.34 ± 0.13 17.91 ± 2.23 
    0.2 
0.08 421.56 ± 102.71 0.43 ± 0.16 3.09 ± 8.15 
0.02 254.60 ± 25.91 0.26 ± 0.10 53.91 ± 3.49 
0.05 191.30 ± 18.33 0.19 ± 26.40 35.48 ± 26.36 
  0.3 
0.08 253.10 ± 16.06 0.28 ± 16.06 7.12 ± 10.07 
0.02 215.26 ± 19.08 0.18 ± 0.08 63.58 ± 10.83 
0.05 270.03 ± 141.66 0.40 ± 0.16 62.76 ± 2.55 
 
0.08       247.22 ±14.91 0.30 ± 0.13 57.08 ± 2.39 
 595 
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 601 
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 603 
 604 
 605 
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 606 
 607 
Table 2 608 
 609 
Effect of chitosan to propranolol HCl ratio on the physical properties of the nanoparticles. 610 
 611 
Chitosan : 
PNL-HCl 
ratio 
Particle size 
(nm) ±SD 
Average PdI 
± SD 
Average ZP 
(mV) 
Amount 
(mg) 
EE (%) 
Drug loading 
(%) 
Drug free 
particles 
191.30 ± 18.33 0.19 ± 26.40 35.48 ± 26.36 0 0 0 
1:1 310.63 ± 69.78 0.41 ± 0.01 55.53 ± 2.20 28.31 ± 0.24 94.38 80.18 
1:2 266.47 ± 14.81 0.21 ± 0.05 51.30 ± 1.74 57.32 ± 0.33 95.53 89.12 
1:3 291.43 ± 22.38 0.29 ± 0.06 48.40 ± 2.43 87.40 ± 0.17 97.12 92.58 
 612 
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 630 
 631 
Table 3 632 
  633 
Effect of changing chitosan concentration on the physical properties of nanoparticles 634 
 635 
PNL-HCl : 
chitosan ratio 
Particle size 
(nm)±SD 
Average 
PdI±SD 
Average ZP 
(mV) ±SD 
Amount (mg) EE (%) 
Drug 
loading (%) 
Drug free 
particles 
191.30 ± 18.33 0.19 ± 26.40 
35.48 ± 
26.36 0 0 0 
 
1:0.5 
 
644.70 ± 31.24 
 
0.76 ± 0.04 
 
17.77 ± 1.07 
 
17.72 ± 0.09 
 
88.60 
 
 
85.52 
 
1:1 166.53 ± 5.55 0.58 ± 0.03 41.90 ± 1.15 17.56 ± 0.14 87.78 77.83 
1:1.5 311.63 ± 26.52 0.73 ± 0.21 49.43 ± 0.50 17.45 ± 0.11 87.26 71.37 
 636 
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 639 
 640 
 641 
 642 
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 644 
 645 
 646 
 647 
 648 
 649 
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 651 
 652 
Table 4 653 
Apparent permeability coefficient of formulations investigated 654 
Formulations Papp (cm/s) 
 
  
Propranolol-HCL solution 7.702 x 10-7 
  
Propranolol-HCl gel 1.844 x 10-7 
  
Propranolol nanoparticle suspension 0.363 x 10-7 
  
Propranolol HCl nanoparticles gel 0.167 x 10-7 
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 670 
 671 
Figure 2. SEM micrographs of wet PNL-HCl-loaded nanoparticles 672 
 673 
 674 
 675 
 676 
 677 
 678 
Figure 3: SEM micrographs of freeze-dried PNL-HCl-loaded nanoparticles 679 
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 688 
 689 
Figure 4:  Rheogram of 1% and 2% carbopol gels at 25 °C and 33 °C 690 
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 703 
Figure 5: Viscosity as a function of shear rate of 1% and 2% carbopol polymer at 25 °C and 704 
33 °C 705 
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Figure 6: Rheogram of 15% poloxamer at 25 °C and 33 °C 722 
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Figure 7: Viscosity as a function of shear rate of 15% poloxamer in presence and absence of 740 
PNL-HCl at 25 °C and 33 °C 741 
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Figure 8:  Rheograms of combination poloxamer 15% and carbopol 1% gels in presence of 751 
propranolol-HCl or nanoparticles at 33°C. 752 
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Figure 9: Viscosity as a function of shear rate of the final formulation consisting of 766 
combination of 15% poloxamer and 1% carbopol in presence of nanoparticles or PNL-HCl at 767 
33 °C 768 
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 770 
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Figure 10: Adhesive capacity of gels at pH 5.5 at room temperature 778 
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Figure 11. Cumulative percentage of propranolol release from different formulations at 37°C 789 
in phosphate buffer pH 6.8 across artificial membrane 790 
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Figure 12. Cumulative percentage of propranolol release from different formulations at 37 °C 806 
in phosphate buffer pH 6.8 across pig ear stratum corneum 807 
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Figure 13a. SEM micrographs of pore of untreated pig stratum corneum 821 
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Figure 13b. SEM micrographs of pore of treated pig stratum corneum 825 
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